Short answer
Oruka Therapeutics, Inc. (ORKA) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$41M
- −67.7% YoY · −29.5% QoQ
Source: XBRL data from the Oruka Therapeutics, Inc. (ORKA) Q2 2026 10-Q on SEC EDGAR. USD.
Oruka Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered operational risk: ORKA-002 Phase 2 trials commenced in psoriasis and hidradenitis suppurativa during February 2026 and recently
- Most material financial update: April 2026 offering issued 9,660,000 shares for $658.3 million net proceeds
- Regulatory risk: FDA or other authorities may require additional data, delaying approval timelines and increasing development costs
- Competitive risk: Increased competition for I&I trial enrollment could delay development and weaken competitive positioning
- Financial risk: At-the-market offering generated $161.4 million net proceeds as of July 31, 2026, with further dilution potential
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oruka Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.